Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 101–200 of 1,007
Gangliosides in cell recognition and membrane protein regulation
Lopez, P. H., & Schnaar, R. L. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.06.001 · Cited by 311
“Vascular endothelial growth factor (VEGF) released from tumors and VEGFR-2, a receptor tyrosine kinase on vascular endothelium, are validated targets for anti-cancer therapy [45].”
The New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308
Raica, M., & Cimpean, A. M. (2010) · Pharmaceuticals · doi:10.3390/ph3030572 · Cited by 304
“promising target for the antiangiogenic therapy and a humanized antibody against VEGF, bevacizumab, was the first antiangiogenic drug introduced in the clinical practice [7].”
BackgroundThe Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
“Therefore, to place tumor cells in a dormant or starvation state by inhibiting the secretion of angiogenic factors or blocking the flow of blood in the blood vessels is a promising treatment strategy for cancer [76].”
BackgroundZhang, F., Tang, Z., Hou, X., Lennartsson, J., Li, Y., Koch, A. W., Scotney, P., Lee, C., Arjunan, P., Dong, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813061106 · Cited by 307
“The hyaloid blood vessel regression and cornea blood vessel survival assays were performed as described (1, 2).”
MethodIn vivo preclinical photoacoustic imaging of tumor vasculature development and therapy
Laufer, J. G., Zhang, E. Z., Treeby, B. E., Cox, B. T., Beard, P. C., Johnson, P., & Pedley, B. (2012) · Journal of Biomedical Optics · doi:10.1117/1.jbo.17.5.056016 · Cited by 308
Cancer invasion and metastasis: changing views
Duffy, M., McGowan, P., & Gallagher, W. (2008) · The Journal of Pathology · doi:10.1002/path.2282 · Cited by 302
“Currently, bevacizumab is undergoing clinical trials in other cancers such as nonsmall cell lung cancer, advanced breast cancer, and renal cancer [101,102].”
BackgroundThe role of low-grade inflammation in the polycystic ovary syndrome
Repaci, A., Gambineri, A., & Pasquali, R. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.08.002 · Cited by 298
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290
“As a result, anti-VEGF therapy has rapidly become an important component of cancer treatment and a major thrust of clinical researc”
BackgroundTie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications
De Palma, M., Murdoch, C., Venneri, M. A., Naldini, L., & Lewis, C. E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.004 · Cited by 287
Nissen, L. J., Cao, R., Hedlund, E.-M., Wang, Z., Zhao, X., Wetterskog, D., Funa, K., Bråkenhielm, E., & Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32479 · Cited by 290
“For example, VEGF is usually expressed at high levels in most tumors and has become an obviously therapeutic target for cancer therapy (1, 3, 6, 14).”
BackgroundStromal cell–derived factor 1 promotes angiogenesis via a heme oxygenase 1–dependent mechanism
Deshane, J., Chen, S., Caballero, S., Grochot-Przeczek, A., Was, H., Li Calzi, S., Lach, R., Hock, T. D., Chen, B., Hill-Kapturczak, N., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061609 · Cited by 283
“20061609 605 In pathophysiological events such as ischemia and infl ammation, host angiogenic responses are increased at the site of injury due, in part, to the release of growth factors such as vascular endothelial growth factor (VEGF) and chemokines such as stromal cell–derived factor 1 (SDF-1) (1).”
BackgroundTargeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
“If those TME-targeting agents are used in combination with myeloablative agents, it will be important to determine whether some agents such as those inhibiting the recruitment of bone marrow–derived cells should be specifically used between courses of intensive and myelosuppressive therapy to prevent the release of pr…”
BackgroundKusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.346 · Cited by 276
Detterbeck, F. C., Franklin, W. A., Nicholson, A. G., Girard, N., Arenberg, D. A., Travis, W. D., Mazzone, P. J., Marom, E. M., Donington, J. S., Tanoue, L. T., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.025 · Cited by 269
“Angiogenesis, a major hallmark of cancer, represents activation and proliferation of endothelial cells owing to tumor cell hypoxia.(20) Neovascularization allows recruitment of inflammatory and immune cells in the stroma, as well as the invasion and circulation of tumor cells.”
BackgroundNotch Signaling in the Vasculature
Gridley, T. (2010) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92009-7 · Cited by 271
“…in treatment of xenograft tumor models in rodents, in clinical trials anti-VEGF-A antibody treatment of several types of cancer only provided an overall survival benefit for patients when it was combined with conventional chemotherapy treatment (Ferrara and Kerbel, 2005; Jain et al., 2006).”
BackgroundLysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease
Li, P., Ge, J., & Li, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0235-9 · Cited by 269
Regulation of Angiogenesis by Hypoxia and Hypoxia‐Inducible Factors
Hickey, M. M., & Simon, M. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76007-0 · Cited by 271
Pochon, S., Tardy, I., Bussat, P., Bettinger, T., Brochot, J., von Wronski, M., Passantino, L., & Schneider, M. (2010) · Investigative Radiology · doi:10.1097/rli.0b013e3181c5927c · Cited by 266
Stewart, D. J., Kutryk, M. J., Fitchett, D., Freeman, M., Camack, N., Su, Y., Siega, A. D., Bilodeau, L., Burton, J. R., Proulx, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.70 · Cited by 268
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets
Zhao, Y., Xiong, W., Li, C., Zhao, R., Lu, H., Song, S., Zhou, Y., Hu, Y., Shi, B., & Ge, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01652-9 · Cited by 249
Engineered nanoparticles for biomolecular imaging
Mahmoudi, M., Serpooshan, V., & Laurent, S. (2011) · Nanoscale · doi:10.1039/c1nr10326a · Cited by 262
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
You, W.-K., Sennino, B., Williamson, C. W., Falcón, B., Hashizume, H., Yao, L.-C., Aftab, D. T., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2527 · Cited by 259
“Inhibitors that target other pathways, such as those involved in tumor invasiveness, are therefore being developed (13, 14).”
Angiogenesis and invasion in glioma
Onishi, M., Ichikawa, T., Kurozumi, K., & Date, I. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-010-0007-z · Cited by 264
“Platelet-derived growth factor (PDGF) secretion by activated endothelial cells recruits pericytes to the site of newly sprouting vessels and aids in establishing a new basement membrane [38, 39].”
Tie2-Expressing Monocytes and Tumor Angiogenesis: Regulation by Hypoxia and Angiopoietin-2
Lewis, C. E., De Palma, M., & Naldini, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1684 · Cited by 261
“The recognition of the critical interactions between immune cells and tumor angiogenesis has led to the suggestion that targeting tumorinfiltrating immune cells may represent a valuable antiangiogenic strategy for cancer treatment ( 5 ).”
BackgroundFeng, Q., Zhang, C., Lum, D., Druso, J. E., Blank, B., Wilson, K. F., Welm, A., Antonyak, M. A., & Cerione, R. A. (2017) · Nature Communications · doi:10.1038/ncomms14450 · Cited by 256
“However, Bevaciuzmb has often failed to give complete responses, with the majority of patients developing resistance 18,20–25 .”
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Fallah, A., Sadeghinia, A., Kahroba, H., Samadi, A., Heidari, H. R., Bradaran, B., Zeinali, S., & Molavi, O. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.022 · Cited by 259
Recent advances in MMP inhibitor design
Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215
“While the primary focus is anticancer MMP inhibitors, the substantial promise that MMP inhibitors offer in other disease states [19–28] will be noted in connection with the subtype focus of new MMP inhibitors.”
BackgroundComplementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hashizume, H., Falcón, B. L., Kuroda, T., Baluk, P., Coxon, A., Yu, D., Bready, J. V., Oliner, J. D., & McDonald, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1977 · Cited by 251
“Inhibitors of vascular endothelial growth factor (VEGF) that are widely used in cancer therapy reduce angiogenesis (1), cause regression of tumor vessels, slow tumor growth (2, 3), and may improve drug delivery (4, 5).”
BackgroundEl‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
“Interference with those crosstalk circuits through intervention of cellular adhesion (highlighted in next paragraph) or tumour-induced recruitment of different stromal cells may be considered as an indirect way of anti-angiogenic therapy (Ferrara and Kerbel, 2005).”
BackgroundLuo, Y., Yang, Z., Yu, Y., & Zhang, P. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.014 · Cited by 244
Elser, C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2871 · Cited by 252
Dietrich, C. F., Nolsøe, C. P., Barr, R. G., Berzigotti, A., Burns, P. N., Cantisani, V., Chammas, M. C., Chaubal, N., Choi, B. I., Clevert, D.-A., et al. (2020) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-1177-0530 · Cited by 242
“Neoangiogenesis is an important target for novel anticancer treatments and many new antiangiogenesis or antivascular treatments aim at destroying or limiting the growth of tumor vessels [241, 242].”
Horsman, M. R., & Siemann, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2848 · Cited by 246
Pulmonary Vascular Destabilization in the Premetastatic Phase Facilitates Lung Metastasis
Huang, Y., Song, N., Ding, Y., Yuan, S., Li, X., Cai, H., Shi, H., & Luo, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4382 · Cited by 247
Novel anti-angiogenic therapies for malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70260-6 · Cited by 246
Antiangiogenic therapies for high-grade glioma
Norden, A. D., Drappatz, J., & Wen, P. Y. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.159 · Cited by 245
Effects of VEGF temporal and spatial presentation on angiogenesis
Silva, E. A., & Mooney, D. J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.052 · Cited by 246
“VEGF has been extensively tested in pre-clinical and clinical studies with a therapeutic objective [6].”
BackgroundA RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
“sorafenib) could be highly effective (42).”
Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aay0555 · Cited by 245
Pregnancy and Breast Cancer: when They Collide
Lyons, T. R., Schedin, P. J., & Borges, V. F. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9119-7 · Cited by 239
“Angiogenesis and lymphangiogenesis, processes that require both MMP activity and deposition of collagen for formation of new vessels, are important steps in both wound healing and tumor progression [93, 94].”
BackgroundMonitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
Korpanty, G., Carbon, J. G., Grayburn, P. A., Fleming, J. B., & Brekken, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1313 · Cited by 245
The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential
Spencer, L., Mann, C., Metcalfe, M., Webb, M., Pollard, C., Spencer, D., Berry, D., Steward, W., & Dennison, A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.026 · Cited by 243
Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M., & Yoneda, T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2355 · Cited by 242
“It is well known that angiogenesis is critical to tumor growth, survival, and metastasis (23).”
Integrins as Therapeutic Targets: Successes and Cancers
Raab-Westphal, S., Marshall, J., & Goodman, S. (2017) · Cancers · doi:10.3390/cancers9090110 · Cited by 241
“Since solid cancers generally develop their own vasculature to allow their progression beyond a small tumor (2 mm diameter) [21], suppressing angiogenesis seemed logical as a therapy for cancer [22].”
BackgroundTargeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Self-citationSelf‐Assembled Smart Nanocarriers for Targeted Drug Delivery
Cui, W., Li, J., & Decher, G. (2016) · Advanced Materials · doi:10.1002/adma.201502479 · Cited by 235
Wakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., Kitamura, H., & Nishimura, T. (2010) · European Journal of Immunology · doi:10.1002/eji.200940157 · Cited by 236
Bashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saab, M., & Noureddin, B. N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.09.031 · Cited by 236
Angiogenesis: from plants to blood vessels
Fan, T.-P., Yeh, J.-C., Leung, K. W., Yue, P. Y. K., & Wong, R. N. S. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.006 · Cited by 233
From snake venom toxins to therapeutics – Cardiovascular examples
Koh, C. Y., & Kini, R. M. (2012) · Toxicon · doi:10.1016/j.toxicon.2011.03.017 · Cited by 228
Sprouty proteins, masterminds of receptor tyrosine kinase signaling
Cabrita, M. A., & Christofori, G. (2008) · Angiogenesis · doi:10.1007/s10456-008-9089-1 · Cited by 229
“mal growth factor (EGF), ephrins, and angiopoietins (Angs), in conjunction with their cognate receptors play a crucial role in blood vessel formation in normal and pathological settings (reviewed in [8, 9]).”
BackgroundArvizo, R. R., Rana, S., Miranda, O. R., Bhattacharya, R., Rotello, V. M., & Mukherjee, P. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.01.011 · Cited by 229
Metabolic catastrophe as a means to cancer cell death
Jin, S., DiPaola, R. S., Mathew, R., & White, E. (2007) · Journal of Cell Science · doi:10.1242/jcs.03349 · Cited by 229
“Angiogenesis inhibitors such as Avastin, which targets vascular endothelial growth factor (Carmeliet, 2005; Ferrara and Kerbel, 2005), can reduce nutrient availability.”
BackgroundIntegrin β1 controls VE-cadherin localization and blood vessel stability
Yamamoto, H., Ehling, M., Kato, K., Kanai, K., van Lessen, M., Frye, M., Zeuschner, D., Nakayama, M., Vestweber, D., & Adams, R. H. (2015) · Nature Communications · doi:10.1038/ncomms7429 · Cited by 229
Masoumi Moghaddam, S., Amini, A., Morris, D. L., & Pourgholami, M. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9337-5 · Cited by 228
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
The role IL-1 in tumor-mediated angiogenesis
Voronov, E., Carmi, Y., & Apte, R. N. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00114 · Cited by 228
“A number of preclinical studies demonstrated a significant inhibition of tumor growth in various types of cancer by blocking VEGF (Ferrara and Kerbel, 2005).”
BackgroundNeuropilin-1 Binds to VEGF121 and Regulates Endothelial Cell Migration and Sprouting
Pan, Q., Chathery, Y., Wu, Y., Rathore, N., Tong, R. K., Peale, F., Bagri, A., Tessier-Lavigne, M., Koch, A. W., & Watts, R. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703554200 · Cited by 204
miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells
Cascio, S., D'Andrea, A., Ferla, R., Surmacz, E., Gulotta, E., Amodeo, V., Bazan, V., Gebbia, N., & Russo, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22126 · Cited by 222
“Vascular endothelial growth factor (VEGF) is the most prominent angiogenic factor promoting tumor progression and a recognized therapeutic target (Ferrara and Kerbel, 2005).”
BackgroundKüchler, A. M., Pollheimer, J., Balogh, J., Sponheim, J., Manley, L., Sorensen, D. R., De Angelis, P. M., Scott, H., & Haraldsen, G. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080014 · Cited by 220
Antiangiogenic Therapy for Cancer: An Update
Al‐Husein, B., Abdalla, M., Trepte, M., DeRemer, D. L., & Somanath, P. R. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1147 · Cited by 216
“8 This complex is localized within the nucleus to start the transcription of certain growth factors such as VEGF, VEGF-C, endothelin-1, platelet-derived growth factor (PDGF)-b, basic fibroblast growth factor, erythropoietin,(9) angiopoietins, interleukin-8, and placenta growth factor.(10) These growth factors stimulat…”
BackgroundDrug resistance to targeted therapeutic strategies in non-small cell lung cancer
Liu, W.-J., Du, Y., Wen, R., Yang, M., & Xu, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107438 · Cited by 216
Xue, Y., Lim, S., Yang, Y., Wang, Z., Jensen, L. D. E., Hedlund, E.-M., Andersson, P., Sasahara, M., Larsson, O., Galter, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2575 · Cited by 212
Anti-Angiogenics: Current Situation and Future Perspectives
Zirlik, K., & Duyster, J. (2018) · Oncology Research and Treatment · doi:10.1159/000488087 · Cited by 216
R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Cao, Y., Cao, R., & Hedlund, E.-M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0337-z · Cited by 215
Yoshioka, K., Yoshida, K., Cui, H., Wakayama, T., Takuwa, N., Okamoto, Y., Du, W., Qi, X., Asanuma, K., Sugihara, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2928 · Cited by 210
Pang, X., Yi, Z., Zhang, X., Sung, B., Qu, W., Lian, X., Aggarwal, B. B., & Liu, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0755 · Cited by 213
Trends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“This is mainly restricted to biological processes connected to the female reproductive cycle (endometrium and ovarian folliculogenesis and the post-ovulatory development of the corpus luteum) and tissue repair associated with wound healing and inflammation [6,9,38].”
BackgroundOkawa, Y., Hideshima, T., Steed, P., Vallet, S., Hall, S., Huang, K., Rice, J., Barabasz, A., Foley, B., Ikeda, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-151928 · Cited by 210
Biology of Angiogenesis and Invasion in Glioma
Tate, M. C., & Aghi, M. K. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.001 · Cited by 213
“Platelet-derived growth factor (PDGF) secretion by activated endothelial cells recruits pericytes to the site of newly sprouting vessels to aid in establishment of a new basement membrane.(31) Of the four PDGF family members (A to D), A and B are the two expressed by gliomas; whereas of the 2 PDGF tyrosine kinase rece…”
BackgroundThree-Dimensional Analysis of Vascular Development in the Mouse Embryo
Walls, J. R., Coultas, L., Rossant, J., & Henkelman, R. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002853 · Cited by 208
“The vascular activities of these pathways are not limited to this developmental time window, but extend to organogenesis [19,20], maintenance of vascular homeostasis in adulthood [8,9,21,22] and states of pathological angiogenesis [23,24,25,26].”
BackgroundA review of the current status of siRNA nanomedicines in the treatment of cancer
Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 210
“In this way, stopping neoangiogenic mechanism could constitute a key strategy to inhibit tumor growth [140].”
Vascular biology of hydrogen sulfide
Kanagy, N. L., Szabo, C., & Papapetropoulos, A. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00329.2016 · Cited by 210
“Increased angiogenesis is also observed in conditions such as psoriasis, arthritis, diabetic retinopathy, and cancer (27, 45, 46).”
BackgroundTugues, S., Koch, S., Gualandi, L., Li, X., & Claesson-Welsh, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 205
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben-Yehuda, O., & Moslehi, J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 201
Cullen, M., Elzarrad, M. K., Seaman, S., Zudaire, E., Stevens, J., Yang, M. Y., Li, X., Chaudhary, A., Xu, L., Hilton, M. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017192108 · Cited by 207
The dual role of thymidine phosphorylase in cancer development and chemotherapy
Bronckaers, A., Gago, F., Balzarini, J., & Liekens, S. (2009) · Medicinal Research Reviews · doi:10.1002/med.20159 · Cited by 206
“[217] [218] [219] [220] The equilibrium between angiogenic and angiostatic proteins, the so-called angiogenic balance, in the microenvironment controls the rate of new blood vessel formation.”
BackgroundWu, F. T. H., Stefanini, M. O., Gabhann, F. M., Kontos, C. D., Annex, B. H., & Popel, A. S. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00941.x · Cited by 203
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Fons, P., Chabot, S., Cartwright, J. E., Lenfant, F., L'Faqihi, F., Giustiniani, J., Herault, J.-P., Gueguen, G., Bono, F., Savi, P., et al. (2006) · Blood · doi:10.1182/blood-2005-12-019919 · Cited by 200
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Pisarsky, L., Bill, R., Fagiani, E., Dimeloe, S., Goosen, R. W., Hagmann, J., Hess, C., & Christofori, G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.028 · Cited by 197
“…identification of vascular endothelial growth factor (VEGF-A) and its receptors as rate-limiting factors for normal and pathological angiogenesis has led to the development of bevacizumab (Avastin), a humanized monoclonal antibody targeting VEGF-A (Ferrara et al., 2004; Ferrara and Kerbel, 2005).”
BackgroundRoles of VEGF-A signalling in development, regeneration, and tumours
Matsumoto, K., & Ema, M. (2014) · Journal of Biochemistry · doi:10.1093/jb/mvu031 · Cited by 198
Connecting Vascular and Nervous System Development: Angiogenesis and the Blood-Brain Barrier
Tam, S. J., & Watts, R. J. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-152829 · Cited by 197
Kanthou, C., & Tozer, G. M. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00651.x · Cited by 197
“The importance of vascular networks in the context of establishment and progression of these diseases, and in particular cancer, has led to the development of the concept of ‘vascular targeting’ for therapy (Folkman 2003; Thorpe 2004; Ferrara 2005; Neri & Bicknell 2005).”
BackgroundMultiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis
Kwon, H. M., Hur, S.-M., Park, K.-Y., Kim, C.-K., Kim, Y.-M., Kim, H.-S., Shin, H.-C., Won, M.-H., Ha, K.-S., Kwon, Y.-G., et al. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.06.004 · Cited by 198
“Pro-angiogenic therapies arewell-known treatments for patientswith ischemic diseases, including peripheral artery disease and acute myocardial infarction, which have the potential to salvage ischemia-associated cardiovascular diseases [1,2].”
BackgroundInfluentialPeptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery
Pearce, T. R., Shroff, K., & Kokkoli, E. (2012) · Advanced Materials · doi:10.1002/adma.201200832 · Cited by 192
Li, Y., Zhang, F., Nagai, N., Tang, Z., Zhang, S., Scotney, P., Lennartsson, J., Zhu, C., Qu, Y., Fang, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33673 · Cited by 194
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
Vimalraj, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.129 · Cited by 186
Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting
Wirzenius, M., Tammela, T., Uutela, M., He, Y., Odorisio, T., Zambruno, G., Nagy, J. A., Dvorak, H. F., Ylä-Herttuala, S., Shibuya, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062642 · Cited by 193
“, the formation of collateral arteries from preexisting arterioles (1, 2).”
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
You, W.-K., & McDonald, D. M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.12.833 · Cited by 190
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Cao, Y. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.002 · Cited by 190
Dai, Y., Hartandi, K., Ji, Z., Ahmed, A. A., Albert, D. H., Bauch, J. L., Bouska, J. J., Bousquet, P. F., Cunha, G. A., Glaser, K. B., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061280h · Cited by 187
Wiley, D. M., Kim, J.-D., Hao, J., Hong, C. C., Bautch, V. L., & Jin, S.-W. (2011) · Nature Cell Biology · doi:10.1038/ncb2232 · Cited by 188
“, and anti-angiogenesis cancer drugs that singularly antagonize VEGF-A activity are only partially effectiv”
VEGF blockade inhibits angiogenesis and reepithelialization of endometrium
Fan, X., Krieg, S., Kuo, C. J., Wiegand, S. J., Rabinovitch, M., Druzin, M. L., Brenner, R. M., Giudice, L. C., & Nayak, N. R. (2008) · The FASEB Journal · doi:10.1096/fj.08-111401 · Cited by 188
“VEGFblocking antibodies, VEGF-receptor antibodies, soluble decoy receptors, and small-molecule inhibitors of VEGF-receptor tyrosine kinase activity are available to inhibit VEGF action in vivo (4, 6). Recent clinical trials with a humanized VEGF monoclonal antibody have shown promising results in human patients with v…”
BackgroundInfluential
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.